These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20041468)

  • 1. Confirmatory analysis for phase III population pharmacokinetics.
    Hu C; Zhang J; Zhou H
    Pharm Stat; 2011; 10(1):14-26. PubMed ID: 20041468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved approach for confirmatory phase III population pharmacokinetic analysis.
    Hu C; Zhou H
    J Clin Pharmacol; 2008 Jul; 48(7):812-22. PubMed ID: 18490499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of population pharmacokinetics in current drug labelling.
    Duan JZ
    J Clin Pharm Ther; 2007 Feb; 32(1):57-79. PubMed ID: 17286790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of nonlinear mixed-model analyses for a pediatric pharmacokinetic study.
    Hartford A; Migoya E; Maganti L; Porras A; Zhang J
    J Biopharm Stat; 2005; 15(3):465-78. PubMed ID: 15920891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A flexible design for multiple armed screening trials.
    Sargent DJ; Goldberg RM
    Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and pharmacodynamics in anesthesia, intensive care and pain medicine.
    Heeremans EH; Proost JH; Eleveld DJ; Absalom AR; Struys MM
    Curr Opin Anaesthesiol; 2010 Aug; 23(4):479-84. PubMed ID: 20610985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness--one larger vs two smaller pivotal studies.
    Shun Z; Chi E; Durrleman S; Fisher L
    Stat Med; 2005 Jun; 24(11):1619-37; discussion 1639-56. PubMed ID: 15568207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linear mixed-effect multivariate adaptive regression splines applied to nonlinear pharmacokinetics data.
    Gries JM; Verotta D
    J Biopharm Stat; 2000 Aug; 10(3):383-98. PubMed ID: 10959918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the choice of doses for phase III clinical trials.
    Lisovskaja V; Burman CF
    Stat Med; 2013 May; 32(10):1661-76. PubMed ID: 23023767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of age on the pharmacokinetics of vapiprost, a thromboxane A2 receptor antagonist, and platelet aggregation: comparison of pharmacokinetics by routine approach and population pharmacokinetics.
    Ohashi K; Aso R
    Int J Clin Pharmacol Res; 2001; 21(2):85-94. PubMed ID: 11824652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
    Mazumdar M; Fazzari M; Panageas KS
    Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.